Back to top

pharmaceuticals: Archive

Zacks Equity Research

Regeneron Initial Data on Multiple Myeloma Drug Encouraging

REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.

REGNNegative Net Change NVSPositive Net Change RHHBYPositive Net Change PFEPositive Net Change

Zacks Equity Research

Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication

FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.

REGNNegative Net Change NVSPositive Net Change RHHBYPositive Net Change PFEPositive Net Change

Sundeep Ganoria

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.

NVONegative Net Change LLYNegative Net Change CRBPNegative Net Change SKYENegative Net Change

Zacks Equity Research

Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases

BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.

REGNNegative Net Change BAYRYPositive Net Change HALOPositive Net Change AMRNPositive Net Change

Zacks Equity Research

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.

BMYNegative Net Change BAYRYPositive Net Change EXELNegative Net Change AMRNPositive Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen

Zacks highlights LLY, GE, and AMGN as top picks, citing strong demand, product pipelines, and defense tailwinds despite some pricing and margin pressures.

GEPositive Net Change LLYNegative Net Change AMGNNegative Net Change

Kinjel Shah

Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

SNYNegative Net Change RHHBYPositive Net Change PFEPositive Net Change NVONegative Net Change MRKNegative Net Change

Zacks Equity Research

FDA Approves GSK's Nucala for Expanded Use in COPD

GSK's Nucala wins FDA nod for COPD with eosinophilic phenotype, marking its fifth indication and strengthening its respiratory portfolio.

REGNNegative Net Change SNYNegative Net Change GSKNegative Net Change VRNAPositive Net Change

Mark Vickery

Top Analyst Reports for Eli Lilly, GE Aerospace & Amgen

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace (GE) and Amgen Inc. (AMGN).

GEPositive Net Change LLYNegative Net Change AMGNNegative Net Change WMPositive Net Change TEAMNegative Net Change WPMPositive Net Change

Ekta Bagri

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

BMRN and NVAX are in the spotlight this week following announcement agreement and regulatory update.

BMRNNegative Net Change MRNANegative Net Change NVAXNegative Net Change PRMEPositive Net Change INZYNo Net Change

Zacks Equity Research

MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot

Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.

SNYNegative Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change

Zacks Equity Research

Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout

SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.

SNYNegative Net Change BIIBNegative Net Change LLYNegative Net Change VIGLPositive Net Change

Kinjel Shah

JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges

While J&J's Innovative Medicines segment is showing a growth trend, the MedTech unit's slowdown is a concern

JNJPositive Net Change AMGNNegative Net Change TEVAPositive Net Change KVUEPositive Net Change

Zacks Equity Research

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.

JNJPositive Net Change MRKNegative Net Change IBRXNegative Net Change CGONNegative Net Change

Zacks Equity Research

Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation

The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.

BAYRYPositive Net Change HALOPositive Net Change AMRNPositive Net Change BBIOPositive Net Change

Zacks Equity Research

ARMP Soars 72% in a Month Following Infectious Disease Study Success

Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.

BAYRYPositive Net Change HALOPositive Net Change AMRNPositive Net Change ARMPPositive Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights Pfizer, Coca-Cola and The Walt Disney

Pfizer, Coca-Cola and The Walt Disney are part of the Zacks top Analyst Blog.

KOPositive Net Change PFEPositive Net Change DISNegative Net Change

Kinjel Shah

AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.

AZNPositive Net Change NVONegative Net Change MRKNegative Net Change LLYNegative Net Change

Ekta Bagri

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).

ILMNNegative Net Change BEAMNegative Net Change QURENegative Net Change NTLANegative Net Change CRSPNegative Net Change VERVNegative Net Change

Sundeep Ganoria

MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots

Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.

PFEPositive Net Change MRNANegative Net Change BNTXNegative Net Change

Ekta Bagri

Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide portfolio, upcoming product launches, promising pipeline candidates and recent positive estimate revisions

GSKNegative Net Change GILDPositive Net Change

Zacks Equity Research

MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug

The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.

AZNPositive Net Change PFEPositive Net Change MRKNegative Net Change

Zacks Equity Research

REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research

Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.

REGNNegative Net Change BAYRYPositive Net Change HALOPositive Net Change ALLONegative Net Change

Nalak Das

Buy 3 Wide Moat Stocks With Double-Digit Near-Term Upside Potential

Three Wide Mode stocks with strong short-term upsides are: PFE, KO, DIS.

KOPositive Net Change PFEPositive Net Change DISNegative Net Change

Zacks Equity Research

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.

AZNPositive Net Change GSKNegative Net Change BIIBNegative Net Change IONSNegative Net Change